Results 261 to 270 of about 34,970 (301)

Tripeptide growth hormone secretagogues

Bioorganic & Medicinal Chemistry Letters, 1998
A series of C-terminus capped dipeptides and tripeptides was synthesized as growth hormone (GH) secretagogues. Among them, tripeptide Aib-D-Trp-D-homoPhe-OEt showed low nanomolar activity in the rat pituitary assay. Thus, we have demonstrated that the GH secretagogue activity of the hexa-hepta-GH releasing peptides can be mimicked at the tripeptide ...
Arthur A. Patchett, Roy G. Smith, Yanping Pan, Ravi P. Nargund, Kang Cheng, Kristine Prendergast, Wanda W.-S. Chan, Greg Morriello, Lihu Yang, Khaled Barakat   +9 more
openaire   +3 more sources

The growth hormone secretagogue receptor (Ghs-R).

Current pharmaceutical design, 2012
The growth hormone secretagogue receptor (GHS-R) is a component of the ghrelin signaling pathway and is involved in mediating the pleiotropic effects of ghrelin.
A. Laviano, A. Molfino, Serena Rianda, F. Rossi Fanelli   +3 more
semanticscholar   +1 more source

Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a.

Journal of Medicinal Chemistry, 2000
The recently discovered growth hormone secretagogue, ghrelin, is a potent agonist at the human growth hormone secretagogue receptor 1a (hGHSR1a). To elucidate structural features of this peptide necessary for efficient binding to and activation of the ...
Maria A. Bednarek, S. Feighner, Sheng-Shung Pong, Karen K. McKee, D. Hreniuk, Maria V. Silva, V. Warren, Andrew D. Howard, L. V. D. Ploeg, James V. Heck   +9 more
semanticscholar   +1 more source

A novel insulin secretagogue is a phosphodiesterase inhibitor

Diabetes, 1995
The arylpiperazine L-686,398 was described as an oral hypoglycemic agent and is shown to be an insulin secretagogue in vitro. The characteristics of its activity were similar to those of the incretin glucagon-like peptide I (GLP-I). We demonstrate that both the peptide and L-686,398 increase the accumulation of cAMP in isolated ob/ob mouse pancreatic ...
Mark D. Leibowitz, Edward J. Brady, Chhabi Biswas, Macro Conti, Richard Saperstein, Vincent C. Manganiello, Catherine A. Cullinan, Peter Zafian, Nancy S. Hayes, Lu-hua Wang, Joel Berger   +10 more
openaire   +3 more sources

Parenteral Nutrition: Substrate and Secretagogue

New England Journal of Medicine, 1972
Maintenance of adequate nutrition in circumstances in which feeding via the gastrointestinal tract is precluded has been the subject of biologic inquiry since Caspar Sotus infused dogs with wine in 1664.1 In terms of current knowledge, the principles of intravenous nutrition can best be understood in the context of two types of clinical situations.
openaire   +3 more sources

Growth hormone secretagogues: out of competition

Analytical and Bioanalytical Chemistry, 2011
Growth hormone secretagogues (GHS) constitute a new GH deficiency treatment increasing exponentially in number and improved potency and bioavailability over the last decade. The growth hormone releasing activity makes these compounds attractive for the artificial improvement of the human sports skills, now that recombinant human growth hormone (rhGH ...
Zoran Nikolovski, Shinji Kageyama, Jordi Segura, Gerard Such-Sanmartín, Armand Pinyot, Ricardo Gutiérrez-Gallego, Jaume Bosch   +6 more
openaire   +3 more sources

Stimulation of pyruvate carboxylation by gastric secretagogues

Experientia, 1980
Pyruvate carboxylation was stimulated by 2 gastric secretagogues, histamine and dibutyryl cyclic AMP, and by butyrate. Thiocyanate, an inhibitor of acid secretion, produced a slight decrease. Avidin significantly reduced acid secretion and this effect was overcome by biotin and oxalacetate.
E. de Bohórquez, J. Chacín
openaire   +3 more sources

Novel inactivating mutations in the GH secretagogue receptor gene in patients with constitutional delay of growth and puberty.

European Journal of Endocrinology, 2011
BACKGROUND A limited number of mutations in the GH secretagogue receptor gene (GHSR) have been described in patients with short stature. Objective To analyze GHSR in idiopathic short stature (ISS) children including a subgroup of constitutional delay of ...
Patrícia N Pugliese-Pires, J. Fortin, Thaís Arthur, A. Latronico, B. Mendonca, S. Villares, I. Arnhold, A. Kopin, A. Jorge   +8 more
semanticscholar   +1 more source

Highly potent growth hormone secretagogues

Bioorganic & Medicinal Chemistry Letters, 2007
During an effort to search for more potent growth hormone secretagogues, we discovered a class of compounds of which the best compound 8 was 7-fold more active in vitro than the best compound in the series we revealed before [Tata, J. R.; Lu, Z.; Jacks, T. M.; Schleim, K. D.; Cheng, K.; Wei, L.; Chan, W.-S.; Butler, B.; Tsou, N.; Leung, K.; Chiu, S.-H.
James R. Tata, Gerard J. Hickey, Bridget Butler, Thomas M. Jacks, Wanda W.-S. Chan, Liente Wei, Kang Cheng, Klaus D. Schleim, Zhijian Lu, Arthur A. Patchett   +9 more
openaire   +3 more sources

Growth Hormone Secretagogues: The Clinical Future

Hormone Research in Paediatrics, 1999
Growth hormone (GH) releasing hexapeptide (GHRP)-6 and other peptidergic and non-peptidergic compounds collectively designated GH secretagogues (GHS) are potent releasers of GH in man. Their clinical future may be envisioned in three areas: therapy of GH-deficient (GHD) states, diagnosis of GHD, and non-endocrinological actions.
Carlos Dieguez, Oreste Gualillo, Dragan Micic, Felipe F. Casanueva, Xesús Casabiell, Manuel Pombo   +5 more
openaire   +3 more sources